# A Phase II Study of Adjuvant Durvalumab Combined With GEMOX/GC Chemotherapy Followed by Lenvatinib Versus Capecitabine in Biliary Tract Cancer.

> **NCT07679399** · PHASE2 · RECRUITING · sponsor: **Peking Union Medical College Hospital** · enrollment: 222 (estimated)

## Conditions studied

- Biliary Tract Neoplasms Immunotherapy

## Interventions

- **COMBINATION_PRODUCT:** Durvalumab plus GEMOX/GC chemotherapy sequentially followed by lenvatinib
- **DRUG:** Capecitabine

## Key facts

- **NCT ID:** NCT07679399
- **Lead sponsor:** Peking Union Medical College Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-06-01
- **Primary completion:** 2027-01-01
- **Final completion:** 2027-06-01
- **Target enrollment:** 222 (ESTIMATED)
- **Last updated:** 2026-07-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07679399

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07679399, "A Phase II Study of Adjuvant Durvalumab Combined With GEMOX/GC Chemotherapy Followed by Lenvatinib Versus Capecitabine in Biliary Tract Cancer.". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07679399. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*